title: Comparison of enrofloxacin and ceftiofur sodium for the treatment of relapse of undifferentiated fever/bovine respiratory disease in feedlot cattle.
abstract: This commercial field trial compared the efficacy of enrofloxacin and ceftiofur sodium in beef cattle at high risk of developing undifferentiated fever (UF), also known as bovine respiratory disease (BRD) that received tilmicosin at feedlot arrival, were diagnosed and initially treated for UF with tilmicosin, and subsequently required a second UF treatment (first relapse). Feedlot cattle (n = 463) were randomly assigned to 2 experimental groups: ENRO or CEF. Second UF relapse, 3rd UF relapse, overall case fatality and BRD case fatality rates were lower in the ENRO group than in the CEF group (P < 0.05). There were no differences in average daily gain (allocation to re-implant date), chronicity, histophilosis case fatality or miscellaneous case fatality rates between the groups (P ≥ 0.05). A per-animal economic advantage of Can$57.08 was calculated for the ENRO group versus the CEF group. In feedlot cattle in western Canada at high risk of developing UF, it was more cost effective to administer enrofloxacin than ceftiofur sodium for treatment of UF relapse.
authors: Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, Jordan University of Science and Technology, Irbid, Jordan. sameeh75@hotmail.com
authors: Sameeh M
authors: SM
authors: Abutarbush
authors: Oliver C
authors: OC
authors: Schunicht
authors: Brian K
authors: BK
authors: Wildman
authors: Sherry J
authors: SJ
authors: Hannon
authors: G Kee
authors: GK
authors: Jim
authors: Tracy I
authors: TI
authors: Ward
authors: Calvin W
authors: CW
authors: Booker
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000401:mortality; D002511:Cephalosporins / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015430:Weight Gain
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D000077422:Enrofloxacin; C053503:ceftiofur; C052319:tilmicosin; D015645:Tylosin